Company profile: Onkaido Therapeutics
1.1 - Company Overview
Company description
- Provider of research into messenger RNA therapeutics aimed at delivering novel oncology drugs to help patients.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Onkaido Therapeutics
Day Zero Diagnostics
HQ: United States
Website
- Description: Provider of whole-genome sequencing–based tools and services for clinical pathogen detection, antimicrobial resistance profiling, and outbreak management, including Blood2Bac to enrich bacterial DNA directly from blood; Keynome ID for species identification; Keynome gAST for resistance profiling; MicrohmDB to support machine learning; and epiXact for pathogen relatedness insights for infection control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Day Zero Diagnostics company profile →
Gen9
HQ: United States
Website
- Description: Provider of next-generation gene synthesis technology enabling high-throughput, automated production of DNA constructs, designed to scale DNA content fabrication with lower cost and higher accuracy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gen9 company profile →
Epizyme
HQ: United States
Website
- Description: Provider of biopharmaceutical research and treatments focused on blood cancer and tumors. Based in Cambridge, MA and founded in 2007, the company translates epigenetic research into programs and offers Bylvay, a non-systemic ileal bile acid transport inhibitor for cholestatic pruritus in Alagille syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epizyme company profile →
Camp4 Therapeutics
HQ: United States
Website
- Description: Provider of RNA-based therapeutics and platform technologies to restore healthy gene expression, including the RAP Platform to map regRNAs and select optimal chemistry, RNA Amplifiers to increase protein expression, programmable antisense oligonucleotide therapeutics targeting regRNA, and CMP-CPS-001 to amplify CPS1 mRNA for potential treatment of urea cycle disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Camp4 Therapeutics company profile →
IMGM Laboratories
HQ: Germany
Website
- Description: Provider of advanced genomic services via a service center in Martinsried, Germany for academic and industrial genome research, serving pharma, diagnostics, academia and biotech. Accredited to DIN EN ISO/IEC 17025 for gene expression analysis using Agilent microarrays and qPCR, and offering first-class NGS, metagenomic sequencing, biomarker discovery, pharmacogenetics, and qPCR/ddPCR-based biodistribution studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IMGM Laboratories company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Onkaido Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Onkaido Therapeutics
2.2 - Growth funds investing in similar companies to Onkaido Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Onkaido Therapeutics
4.2 - Public trading comparable groups for Onkaido Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →